Marroquin v. Pfizer, Inc.
367 F. Supp. 3d 1152
E.D. Cal.2019Background
- Plaintiff Gilbert Marroquin sued Pfizer and Mylan after his wife Agapita Marroquin died of pulmonary disease allegedly caused by amiodarone administered in April 2016; amiodarone is the generic for Cordarone.
- FAC asserted seven California-law claims: strict products liability (manufacturing theory), negligence-based products liability, breach of warranty, intentional misrepresentation, negligent misrepresentation, concealment, and punitive damages.
- Defendants moved to dismiss under Fed. R. Civ. P. 12(b)(6); Pfizer also argued Rule 9(b) defects for fraud-based claims; Mylan additionally argued federal preemption under Mensing/Bartlett for label-based claims against generics/distributors.
- The court took judicial notice of FDA-approved Cordarone labels (including a 2015 label) showing explicit, extensive pulmonary toxicity warnings.
- The court found the FAC conclusory and insufficiently particular: it failed to plead a manufacturing defect with factual detail, did not plausibly allege inadequate warnings given the FDA label, and lumped defendants together for fraud claims in violation of Rule 9(b).
- The court dismissed all claims, granted leave to amend generally but dismissed Mylan-related failure-to-warn claim (fourth cause) with prejudice due to impossibility preemption concerns as to distributors/generic sameness doctrine.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Sufficiency of products-liability (manufacturing) pleading | Marroquin alleges amiodarone was defective and caused death; tracks CACI manufacturing instruction | Defendants: pleading is conclusory; no factual description how product deviated from intended design or other units | Dismissed — FAC fails to allege how a manufacturing defect existed; leave to amend allowed |
| Failure-to-warn (strict liability) | Warnings adequacy is a fact question; plaintiff need not show label now; physician may not have seen the same label | Pfizer: FDA label (Cordarone) clearly warns of pulmonary toxicity; learned intermediary rule; Mylan: preemption (Mensing/Bartlett) prevents state-law labeling claims against generics/distributors | Dismissed — pleading insufficient as to inadequacy and causation given the FDA label; Mylan’s failure-to-warn claim dismissed with prejudice under preemption doctrine |
| Negligence, breach of warranty | Alleged breaches in research/manufacture/marketing and implied warranty of fitness | Defendants: claims duplicate product-liability failures, plaintiffs must identify defect/warning inadequacy and physician reliance; implied warranty fails because patient relied on physician | Dismissed — claims lack factual allegations identifying defect or showing manufacturer-produced warning causation; leave to amend generally allowed |
| Fraud-based claims (intentional/negligent misrepresentation, concealment) | Alleged misrepresentations that drug was "safe, fit, effective" and concealment of risks | Defendants: claims sound in fraud and fail Rule 9(b) — lumping, no who/what/when/where/how, no identifying speakers; continued reliance unlikely where prescribing physician controls | Dismissed — plaintiff concedes intentional claim fails Rule 9(b); negligent misrepresentation and concealment also fail for same reasons; leave to amend denied only where futile |
Key Cases Cited
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading must state a plausible claim)
- Brown v. Superior Court, 44 Cal.3d 1049 (drug manufacturers not strictly liable for design defects; manufacturing and warning theories recognized)
- Carlin v. Superior Court, 13 Cal.4th 1104 (learned intermediary rule: duty to warn runs to prescribing physician)
- Merrill v. Navegar, Inc., 26 Cal.4th 465 (products-liability causation requirement and negligence additional element)
- PLIVA, Inc. v. Mensing, 564 U.S. 604 (generic manufacturers must match brand labeling; state-law duties to change label can be preempted)
- Mutual Pharm. Co. v. Bartlett, 570 U.S. 472 (impossibility preemption where generic cannot lawfully alter formulation/label)